Pfizer Inc. $PFE Holdings Trimmed by Fishman Jay A Ltd. MI

Fishman Jay A Ltd. MI reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 2.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 275,531 shares of the biopharmaceutical company’s stock after selling 6,643 shares during the period. Pfizer makes up about 0.6% of Fishman Jay A Ltd. MI’s investment portfolio, making the stock its 26th largest position. Fishman Jay A Ltd. MI’s holdings in Pfizer were worth $6,679,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. GKV Capital Management Co. Inc. purchased a new stake in Pfizer during the first quarter valued at about $27,000. North Capital Inc. purchased a new stake in shares of Pfizer in the 1st quarter valued at approximately $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer in the 1st quarter valued at approximately $28,000. Horizon Financial Services LLC purchased a new position in Pfizer during the 1st quarter worth approximately $35,000. Finally, WPG Advisers LLC purchased a new position in Pfizer during the 1st quarter worth approximately $35,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 1.1%

Shares of NYSE:PFE opened at $27.37 on Monday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company has a market cap of $155.59 billion, a P/E ratio of 14.56, a P/E/G ratio of 0.88 and a beta of 0.55. The stock’s 50-day moving average is $24.67 and its 200-day moving average is $24.12. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the company posted $0.60 earnings per share. Pfizer’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Morgan Stanley raised their target price on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Bank of America upped their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday. Citigroup increased their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday. Finally, Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $28.41.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.